Nicola Fazio
Nicola Fazio, MD, PhD is an expert in Oncology at Fondazione IRCCS Istituto Nazionale dei Tumori (Italy). As of October 2026, ScienceLeadR ranks Nicola Fazio in the top 1% of experts worldwide for Carcinoma and Gastrointestinal Neoplasms. Nicola Fazio has authored 484 publications, the most recent in 2026, and is an investigator in 33 clinical trials, 15 of them ongoing. SLR score: 2,242 (community average: 125). How the SLR is computed.
LeadR Profile
Oncology
Subspecialties: Endocrinology - Surgery - Hematology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Short Biography
Nicola Fazio graduated at the University of L’Aquila, Italy, Faculty of Medicine and Surgery, in 1988, where he also specialised in Internal Medicine in 1993.
In 2002 he specialized in Medical Oncology at University of Milan.
In 2013 he gained his Ph.D. in Digestive Oncology at the University of Rome “La Sapienza”.
Fazio is currently Director of the Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumours and Director of the Programme in Digestive and Neuroendocrine Tumours at the European Institute of Oncology, in Milan, Italy, where he has been working since 1995.
Since 2015 he is head of the IEO ENETS Centre of Excellence for GEP NENs and lung NETs.
From 2013 to 2019 he served as coordinator of the Italian (AIOM/ITANET) neuroendocrine neoplasms guidelines.
Fazio is full member of American Society of Clinical Oncology (ASCO) since 2000 and full member of the European Society for Medical Oncology (ESMO) since 2002. He has
been serving as ESMO Faculty Coordinator for Neuroendocrine, Endocrine and
CUP for the period 2016-2019 and he is currently member of the NET end endocrine tumors ESMO faculty. He served as chair of the ESMO NEN Preceptorship in 2017, 2018, 2019 and 2021 and chair of the ESMO NEN Advanced Course in 2019 and 2021.
Since 2015 he has been member of the European Neuroendocrine Tumour Society (ENETS) Advisory Board and he served as Advisory Board Speaker for the period 2018-2020. Since 2020 he is member of ENETS executive committee. Between 2021 and 2024 he served as chair of the ENETS certification of centers of excellence and co-chair of the academic database research activity. In 2024 he has been nominated ENETS President Elect; he will take over the active presidency in March 2026.
His research has focused on multidisciplinary and translational clinical research in neuroendocrine neoplasms and gastrointestinal cancers.
He has participated as invited speaker in several national and international meetings and has co-authored more than 300 publications in peer-reviewed journals.
Organizations
Career arc: 1995 - 2026
Number : 484
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
Clinical Studies 33
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Ongoing Clinical Trials
15 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Phase 3 study of RMC 6236 in patients with previously treated metastatic PDAC 2024-516063-89-00 — adenocarcinoma, therapeutics | Phase 3 | Active not recruiting | 2025 |
| A study in people with advanced extrapulmonary neuroendocrine cancer to compare obrixtamig plus carboplatin and etoposide treatment with standard chemotherapy 2025-523869-22-00 — neoplasms, multiple chronic conditions, drug therapy, therapeutics, etoposide, carboplatin, carcinoma, neuroendocrine, chemotherapy, carcinoma | Phase 3 | Recruiting | 2026 |
| A trial to learn how well sonesitatug vedotin and capecitabine with or without rilvegostomig work and how safe they are in adults with cancers of the stomach and esophagus 2024-519787-40-00 — stomach, esophagus, esophagogastric junction, neoplasms, adenocarcinoma, work, therapeutics, esophageal neoplasms, capecitabine, stomach neoplasms | Phase 3 | Not yet recruiting | 2026 |
| 177Lu edotreotide compared to everolimus in neuroendocrine tumors of the lung and thymus 2022-502154-13-00 — lung, somatostatin, safety, neoplasms, everolimus, neuroendocrine tumors, receptors, somatostatin, patient reported outcome measures, thymus gland, therapeutics, receptors, peptide | Phase 3 | Recruiting | 2023 |
| Phase II open label single arm study of PembrolizumAb combiNeD with cisplatin or carbOplatin and etoposide in treatment na ve advanced meRkel cell cArcinoma (MCC) (PANDORA Trial) 2022-500988-12-00 — cells, merkel cells, therapeutics, genes, mcc, etoposide, carboplatin, carcinoma, merkel cell, carcinoma | Phase 2 | Recruiting | 2023 |
LeadR Networks
Main global connection map